UK-based research and development (R&D) firm Cambridge Consultants has developed a new digital platform, called Verum, to enhance healthcare delivery.
Designed to remotely monitor patients, the platform leverages machine learning to predict health conditions or diseases.
Go deeper with GlobalData
For proof-of-concept, Verum is being tested to measure and monitor the stress levels of patients participating in clinical trials. Stress is attributed to 30% of average trial drop-out rates.
Cambridge Consultants said that identification and reduction of the effect of patient stress on trial outcomes could improve efficiency.
Cambridge Consultants Digital Health head Jaquie Finn said: “The rising cost of clinical trials, combined with the commercial risks of failure, mean it’s vital we’re able to harness the power of AI and continuous patient monitoring to mitigate the impact of stress on clinical trial outcomes.
“Verum informs better adaptive trial design through bigger, real-time contextualised data sets and will mark a step-change in the efficiency of clinical trials.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataVerum is designed as a wearable that is integrated with sensors. It is accompanied by a data collection app and a widget for healthcare dashboards that delivers patient-specific predictions and notifications.
In addition to machine learning, the platform utilises biometric data including voice and electromyography (EMG) to provide better insights into clinical outcomes.
During trials, Verum can deliver real-time triggers and alerts about participant stress levels, in turn enabling clinicians, nurses and trial coordinators to address the effect of stress on compliance.
Cambridge Consultants believes that the capability of the platform to offer contextualised population as well as patient-level data could boost precision medicine, post-market surveillance and drug development.
The firm hopes to expand the platform’s application for the detection of neurological disorders, closed loop therapeutics development, rehabilitation and remote patient monitoring, among others.
Last month, Cambridge Consultants unveiled a new single-use miniature endoscope camera, Leap, to facilitate imaging during intravascular surgery.
